Please assess the completion status of the following clinical trial:

Trial Title: A Study for Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Have type 2 diabetes mellitus for at least 6 months prior to entering the trial.~* Treated with diet and exercise alone or in combination with at least 1000 milligrams (mg)/day of metformin for at least 2 months prior to screening.~* Have a glycosylated fraction of hemoglobin A (HbA1c) value of 7.0% - 10.0% at screening~* Women of child-bearing potential must test negative for pregnancy at screening and agree to abstain from heterosexual intercourse for the duration of the study, or use 2 effective forms of birth control during the study.~* Have a body mass index (BMI) between 25 and 40 kilograms per square meters kg/m\^2) at screening~* Stable weight during the 3 months prior to screening.~Exclusion Criteria:~* Use any antidiabetic agent other than metformin during the 2 months prior to screening.~* Have a gastrointestinal disease that significantly impacts gastric emptying or motility or have undergone bariatric surgery.~* Are currently taking prescription or over-the counter medications to promote weight loss.~* Have been previously diagnosed with pancreatitis~* Women who are breastfeeding.~* Have a history of myocardial infarction, unstable angina, coronary artery bypass graft (CABG), percutaneous coronary intervention, transient ischemic attack, stroke or decompensated congestive heart failure in the past 6 months.~* Have poorly controlled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 0.5 mg LY2428757 (Type: EXPERIMENTAL): Once weekly, subcutaneous injection of 0.5 milligram (mg) LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
- 2.0 mg LY2428757 (Type: EXPERIMENTAL): Once weekly, subcutaneous injection of 2.0 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
- 6.2 mg LY2428757 (Type: EXPERIMENTAL): Once weekly, subcutaneous injection of 6.2 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
- 12.0 mg LY2428757 (Type: EXPERIMENTAL): Once weekly, subcutaneous injection of 12.0 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
- 17.6 mg LY2428757 (Type: EXPERIMENTAL): Once weekly, subcutaneous injection of 17.6 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
- Placebo (Type: PLACEBO_COMPARATOR): Once weekly, subcutaneous injection of placebo for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete